Recent briefings covering the 30-day period through early August 2026 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated from 2026-06-09 through 2026-08-04 each noted the absence of new filings beyond routine continuations, indicating a period of limited publicly disclosed corporate activity during the covered interval [Brief - 2026-08-04] [Brief - 2026-07-27] [Brief - 2026-07-19].
AbbVie's trailing twelve-month revenue as of 2026-06-30 stood at $64.39 billion, representing year-over-year growth of 10.16%. Net income for the same period was $6.31 billion, yielding a net margin of 9.80%. Gross margin was recorded at 65.73% and operating margin at 26.20%. EPS grew 290.38% year-over-year on a TTM basis. The company held $6.57 billion in cash against total debt of $64.50 billion. The trailing P/E ratio was 70.47 [SEC 10-Q - ABBV - 2026-06-30].
Institutional ownership data reflects notable position changes across several prominent filers. Citadel added approximately 76% to its ABBV position, while Millennium increased its holding by approximately 35%. AQR Capital reported an increase of approximately 127% to its position. Conversely, Bridgewater reduced its position by approximately 61% during the same reporting period. These movements collectively represent the material institutional changes that motivated this report [SEC 13F - Citadel - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macroeconomic backdrop as of the report generation date shows the 10-year US Treasury yield at 4.63% and the 2-year yield at 4.15%, producing a normal yield curve with a spread of approximately 48 basis points [FRED DGS10] [FRED DGS2]. AbbVie carries a substantial debt load of $64.50 billion, and the current interest rate environment is relevant context for assessing the cost profile associated with that debt structure [SEC 10-Q - ABBV - 2026-06-30].